Table 1. Study groups by CML category... | American Society of Hematology

Table 1.

Study groups by CML category and protocol registration

Study registration	Study	Chronic	Clonal evolution only	Accelerated, no clonal evolution	Accelerated + clonal evolution
FDA pivotal, chronic	Novartis 110 (N = 149)²⁵	130	19	—	—
FDA pivotal, accelerated	Novartis 109 (N = 59)²⁶	—	—	32	26
Expanded access, chronic	Novartis 113 (N = 112)²⁸	106	5	1	—
Expanded access, accelerated	Novartis 114 (N = 179)²⁹	59	46	49	25
Total		295	70	82	51

Study registration	Study	Chronic	Clonal evolution only	Accelerated, no clonal evolution	Accelerated + clonal evolution
FDA pivotal, chronic	Novartis 110 (N = 149)²⁵	130	19	—	—
FDA pivotal, accelerated	Novartis 109 (N = 59)²⁶	—	—	32	26
Expanded access, chronic	Novartis 113 (N = 112)²⁸	106	5	1	—
Expanded access, accelerated	Novartis 114 (N = 179)²⁹	59	46	49	25
Total		295	70	82	51

— indicates not applicable.